ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ALX ONCOLOGY HOLDINGS INC.
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/11ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponso..
CI
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
08/09Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discoun..
MT
08/08ALX ONCOLOGY : Reports Second Quarter 2022 Financial Results and Provides Clinical Develop..
PU
08/08ALX ONCOLOGY : Corporate Presentation
PU
08/08ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Mont..
CI
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
08/01ALX Oncology Receives FDA Fast-Track Designation for Head, Neck Cancer Drug
MT
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
GL
08/01ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm..
CI
06/29ALX Oncology Secures FDA Orphan Drug Designation for Evorpacept
MT
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
06/29ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
AQ
06/29ALX Oncology's Evorpacept Gets FDA Designation for Leukemia
DJ
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from Russell Small Cap Comp Growth Ind..
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell Microcap Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from Russell 2000 Growth Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell Microcap Value Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell 2000 Value Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell Small Cap Comp Value Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from Russell 2500 Growth Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from Russell 3000 Growth Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell 3000 Value Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell 3000E Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from Russell 3000E Growth Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell 2500 Value Index
CI
06/24ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) added to Russell 3000E Value Index
CI
06/21ALX ONCOLOGY HOLDINGS INC.(NASDAQGS : ALXO) dropped from S&P Biotechnology Select Industry..
CI
06/07ALX ONCOLOGY : Corporate Presentation
PU
06/06Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Ra..
MT
06/03ALX Oncology Announces Evorpacept Clinical Program Updates
GL
06/03ALX Oncology Announces Evorpacept Clinical Program Updates
GL
06/03ALX Oncology Holdings Inc Announces Evorpacept Clinical Program Updates
CI
06/01ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference
GL
05/19Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $48 From $70, Reiterates..
MT
05/09ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop..
GL
05/09ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
05/09ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/12ALX ONCOLOGY : Appoints Itziar Canamasas, Ph.D., to its Board of Directors - Form 8-K
PU
04/12ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors
GL
04/12ALX Oncology Appoints Itziar Canamasas, Ph.D., to Its Board of Directors
CI
03/28ALX Oncology Holdings Files $450 Million Mixed Shelf
MT
03/25ALX ONCOLOGY : Corporate Presentation
PU
03/14Cantor Fitzgerald Adjusts Price Target for ALX Oncology to $60 From $103, Maintains Ove..
MT
03/02ALX Oncology Doses First Patient in Phase 2/3 Trial of Evorpacept in Gastric, Gastroeso..
MT
03/02ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept..
GL
03/02ALX Oncology Holdings Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of E..
CI
03/01Stifel Adjusts ALX Oncology Holdings' Price Target to $36 from $60, Maintains Buy Ratin..
MT
03/01HC Wainwright Adjusts Price Target on ALX Oncology Holdings to $80 From $100, Reiterate..
MT
02/28ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31..
CI
02/28ALX ONCOLOGY : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Cl..
PU
02/28ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C..
AQ
02/28ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
CI
02/14Credit Suisse Lowers ALX Oncology Holdings' Price Target to $41 from $53, Maintains Out..
MT
01/27ALX Oncology Gets FDA Orphan Drug Designation for Evorpacept
DJ
01/27ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
01/27ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment..
GL
01/18ALX ONCOLOGY : Corporate Presentation
PU
01/11TRANSCRIPT : ALX Oncology Holdings Inc. Presents at JPMorgan 40th Annual Healthcare Confer..
CI
01/10ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
GL
01/10ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
GL
01/04ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021NORTH AMERICAN MORNING BRIEFING : Stocks to Rise -2-
DJ
2021ALX Oncology Shares Lower After Jefferies Downgrade, Price Target Cut
MT
2021Jefferies Cuts ALX Oncology Holdings to Hold From Buy, Price Target to $25 From $65
MT
2021INSIDER SELL : Alx Oncology Holdings
MT
2021Credit Suisse Drops ALX Oncology's PT to $53 from $83 As Updated Evorpacept Trial Data ..
MT
2021DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Ind..
PR
2021ALX ONCOLOGY : ASH Conference Call Presentation
PU
2021INSIDER SELL : Alx Oncology Holdings
MT
2021ALX ONCOLOGY : Corporate Presentation
PU
1  2  3  4Next
Upcoming event on ALX ONCOLOGY HOLDINGS INC.